Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,426 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer.
Gotto GT, Yip SM, Shayegan B, O'Sullivan DE, Wallis CJD, Basappa NS, Cagiannos I, Hamilton RJ, Ferrario C, Fernandes R, Danielson B, Saad F, Hotte SJ, Cheung WY, Boyne DJ, Chan K, Osborne B, Zardan A, Malone S. Gotto GT, et al. Among authors: saad f. Can Urol Assoc J. 2024 Aug 30. doi: 10.5489/cuaj.8691. Online ahead of print. Can Urol Assoc J. 2024. PMID: 39470659 Free article.
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Saad F, Hotte S, North S, Eigl B, Chi K, Czaykowski P, Wood L, Pollak M, Berry S, Lattouf JB, Mukherjee SD, Gleave M, Winquist E; Canadian Uro-Oncology Group. Saad F, et al. Clin Cancer Res. 2011 Sep 1;17(17):5765-73. doi: 10.1158/1078-0432.CCR-11-0859. Epub 2011 Jul 25. Clin Cancer Res. 2011. PMID: 21788353 Clinical Trial.
Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience.
Yafi FA, Aprikian AG, Fradet Y, Chin JL, Izawa J, Rendon R, Estey E, Fairey A, Cagiannos I, Lacombe L, Lattouf JB, Bell D, Saad F, Drachenberg D, Kassouf W. Yafi FA, et al. Among authors: saad f. BJU Int. 2012 Nov;110(9):1317-23. doi: 10.1111/j.1464-410X.2012.11133.x. Epub 2012 Apr 13. BJU Int. 2012. PMID: 22500588
Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration.
Fairey AS, Kassouf W, Estey E, Tanguay S, Rendon R, Bell D, Izawa J, Chin J, Kapoor A, Matsumoto E, Black P, So A, Lattouf JB, Saad F, Drachenberg D, Cagiannos I, Lacombe L, Fradet Y, Jacobsen NE. Fairey AS, et al. Among authors: saad f. BJU Int. 2013 Oct;112(6):791-7. doi: 10.1111/j.1464-410X.2012.11474.x. Epub 2012 Nov 13. BJU Int. 2013. PMID: 23148712
Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada.
Metcalfe M, Kassouf W, Rendon R, Bell D, Izawa J, Chin J, Kapoor A, Matsumoto E, Lattouf JB, Saad F, Lacombe L, Fradet Y, Fairey A, Jacobson NE, Drachenberg D, Cagiannos I, So A, Black P. Metcalfe M, et al. Among authors: saad f. Can Urol Assoc J. 2012 Dec;6(6):455-62. doi: 10.5489/cuaj.12146. Can Urol Assoc J. 2012. PMID: 23282664 Free PMC article.
1,426 results